Radiolabeled Monoclonal Antibody Targets Bone Marrow in AML Transplant Patients

Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

ORLANDO--A preparative regimen employing a radiolabeled monoclonal antibody (MoAb), coupled with busulfan (Myleran) and cyclophosphamide (Cytoxan, Neosar), yielded a low relapse rate in patients with acute myelogenous leukemia (AML) undergoing bone marrow transplantation (BMT) while in first remission.

ORLANDO--A preparative regimen employing a radiolabeled monoclonal antibody(MoAb), coupled with busulfan (Myleran) and cyclophosphamide (Cytoxan,Neosar), yielded a low relapse rate in patients with acute myelogenousleukemia (AML) undergoing bone marrow transplantation (BMT) while in firstremission.

"Although follow-up is short," Dana C. Matthews, MD, saidin her presentation at the ASH meeting, "we are very encouraged bythe low relapse rate."

Despite advances over the last two decades, AML patients undergoingBMT during first remission have shown no appreciable improvements in disease-freesurvival, said Dr. Matthews, of the Fred Hutchinson Cancer Research Center.

Increasing the radiation dose used in the preparative regimen lowersthe relapse rate in these patients, according to previous studies conductedat Hutchin-son, but has no impact on overall disease-free survival, shesaid. Moreover, the higher radiation doses produce greater toxicity tonormal organs, eg, the liver.

In contrast, use of an anti-CD45 murine MoAb labeled with iodine-131enabled Dr. Matthews and her colleagues to safely deliver almost 11 Gyof radiation to marrow in 17 AML patients, ranging in age from 16 to 55years, who were to receive a marrow graft from an HLA-matched, relateddonor.

In this phase I/II study, patients first received a trace dose of theradiolabeled MoAb followed by gamma camera imaging and a bone marrow biopsyto determine the estimated dose to target organs (spleen, bone marrow)and nontarget organs (liver, lung, kidney). These individualized radiationabsorbed doses were used to calculate desired therapeutic doses of theMoAb, Dr. Matthews said.

Therapeutic Doses

The therapeutic doses were administered over 4 to 8 hours on the 14thday before transplantation and were followed by treatment with busulfan(16 mg/kg/day) on the eighth through fifth days prior to grafting and cyclophosphamide(120 mg/kg/day) on the third and second days preceding BMT.

She noted that no grade 3 or 4 regimen-related toxicity occurred inthe first four patients, who received a lower radiation dose (105 to 152mCi of iodine-131, which delivered an average of 3.5 Gy to the liver and9.2 Gy to the marrow).

Use of a higher level of radiation (101 to 263 mCi of iodine-131, deliveringan average of 5.25 Gy to the liver and 10 Gy to the marrow) in the next13 patients resulted in three cases of grade 3 toxicity (mucositis) andone instance of grade 4 toxicity. The patient with grade 4 toxicity diedof multiorgan failure, she added.

In the surviving 16 patients, no relapses have occurred over a medianfollow-up of 14 months. One patient is still alive 33 months after transplant.Although continued accrual and longer follow-up are needed to ascertaintrue toxicity rates and the durability of remissions, Dr. Matthews believesthat the new therapy "should improve disease-free survival in AMLpatients in first remission."

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.